27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Below are five more biotech companies looking to raise money this week.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Puma Biotechnology (NYSE: PBYI) is offering one million shares of stock. The underwriters are Bank of America Merrill Lynch, J.P. Morgan, Leerink Partners, and Cowen. The deal is expected to price Wednesday night and trade Thursday.
Versartis (NASDAQ: VSAR) is offering $75 million of stock. The underwriters are Citigroup, Credit Suisse, Cowen, Canaccord Genuity, and SunTrust Robinson Humphrey. The deal is expected to price Wednesday night and trade Thursday.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Zafgen (NASDAQ: ZFGN) is offering 2,840,909 shares of stock. The underwriters are Leerink, Cowen, Canaccord, and JMP Securities. The deal is expected to price Wednesday night and trade Thursday.
The company is expected to report Phase 3 results of Beloranib for Prader-Willi Syndrome in the fourth quarter. Vitae Pharmaceuticals (NASDAQ: VTAE) is offering 3 million shares of stock. The underwriters are Stifel, BMO Capital, Piper Jaffray, JMP Securities, and Wedbush. The deal is expected to price Thursday night and trade Friday.
The company is expecting to report Phase 2 data of VTP-34072 for Type 2 diabetes in the first half of 2015.
Verastem (NASDAQ: VSTM) is offering $40 million worth of stock. The underwriters are Jefferies, Leerink Partners, Guggenheim, and Oppenheimer. The deal is expected to price Thursday night and trade Friday.
Verastem is expected to announce an interim analysis for its Phase II trial of VS-6063 for mesothelioma in the second quarter.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.